[1] Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem[J].Clin Microbiol Rev,2007,20(1):133-163.
[2] Newton K, Dixit VM. Signaling in innate immunity and inflammation[J].Cold Spring Harb Perspect Biol,2012,4(3):a006049.
[3] Ellis D. Amphotericin B: spectrum and resistance[J]. J Antimicrob Chemother,2002, 49(Suppl 1):7-10.
[4] Kafetzis DA, Velissariou IM, Stabouli S,et al. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds[J]. Int J Antimicrob Agents,2005,25(1):26-30.
[5] Razonable RR, Henault M, Lee LN,et al. Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of toll-like receptors 1 and 2[J].Antimicrob Agents Chemother,2005,49(4):1617-1621.
[6] Sau K, Mambula SS, Latz E,et al. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism[J].J Biol Chem,2003,278(39):37561-37568.
[7] Bellocchio S, Gaziano R, Bozza S,et al. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4[J].J Antimicrob Chemother,2005,55(2):214-222.
[8] Matsuo K, Hotokezaka H, Ohara N,et al. Analysis of amphotericin B-induced cell signaling with chemical inhibitors of signaling molecules[J].Microbiol Immunol,2006,50(4):337-347.
[9] Wheeler RT, Kombe D, Agarwala SD,et al. Dynamic, morphotype-specific Candida albicans beta-glucan exposure during infection and drug treatment[J].PLoS Pathog,2008,4(12):e1000227.
[10] Dennehy KM, Brown GD. The role of the beta-glucan receptor Dectin-1 in control of fungal infection[J]. J Leukoc Biol, 2007,82(2):253-258.
[11] Denning DW. Echinocandins: a new class of antifungal[J]. J Antimicrob Chemother, 2002,49(6):889-891.
[12] Moretti S, Bozza S, D'Angelo C,et al. Role of innate immune receptors in paradoxical caspofungin activity in vivo in preclinical aspergillosis[J]. Antimicrob Agents Chemother,2012,56(8):4268-4276.
[13] Salvenmoser S, Seidler MJ, Dalpke A,et al. Effects of caspofungin,Candida albicans and Aspergillus fumigatus on toll-like receptor 9 of GM-CSF-stimulated PMNs[J]. FEMS Immunol Med Microbiol,2010,60(1):74-77.
[14] Moretti S, Bozza S, Massi-Benedetti C,et al. An immunomodulatory activity of micafungin in preclinical aspergillosis[J]. J Antimicrob Chemother,2014,69(4):1065-1074.
[15] Simitsopoulou M, Roilides E, Paliogianni F,et al.Immunomodulatory effects of voriconazole on monocytes challenged with Aspergillus fumigatus: differential role of Toll-like receptors[J]. Antimicrob Agents Chemother,2008,52(9):3301-3306.
[16] Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options[J]. J Med Microbiol,2006,55(Pt 7):809-818.
[17] Shoham S, Marr KA. Invasive fungal infections in solid organ transplant recipients[J]. Future Microbiol,2012,7(5):639-655.
[18] Hagerty JA, Ortiz J, Reich D, Manzarbeitia C. Fungal infections in solid organ transplant patients[J]. Surg Infect (Larchmt), 2003,4(3):263-271.
[19] Blanco JL, Garcia ME. Immune response to fungal infections[J]. Vet Immunol Immunopathol,2008,125(1-2):47-70.
[20] Plantinga TS, Johnson MD, Scott WK,et al.Toll-like receptor 1 polymorphisms increase susceptibility to candidemia[J]. J Infect Dis,2012,205(6):934-943.
[21] Bochud PY, Chien JW, Marr KA,et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation[J]. N Engl J Med,2008,359(17):1766-1777.
[22] 李平,温海,朱红梅,等.隐球菌免疫相关的甘露糖受体MR重组腺病毒载体的构建及鉴定[J]. 中国真菌学杂志,2012,7(2):70-72. |
